We conceived the co-clinical platform as an innovative approach to improve the design, speed and outcomes of rational and personalized clinical treatments 1 . The power of this approach lies in harnessing data gained from preclinical studies performed in several genetic mouse models and combining them with the concurrent investigation of therapies, either conventional or experimental, in human patients.
A r t i c l e s and Pten and Trp53 double-null mice (Pbsn-cre4; Pten fl/fl ; Trp53 fl/fl ) to test the hypothesis that advanced prostate cancers with distinct genetic make-ups respond differentially to ADT. For each genetically distinct tumor type, we generated cohorts of 15 mutant mice that were castrated at the age at which they developed prostate cancer (high-grade prostatic intraepithelial neoplasia (HG-PIN) characterized by focal invasive carcinoma) as previously reported 4, 5, 13 . Age-matched non-castrated cohorts were used as controls. All cohorts were monitored for 3 months after castration.
Groups of five mice from each cohort (castrated and non-castrated) were sacrificed at 1, 2 and 3 months after castration for histopathological analysis (the timeline of this analysis is given in Fig. 1a) . The mice sacrificed 3 month after castration were also analyzed by magnetic resonance imaging (MRI) for tumor volume assessment on a monthly schedule ( Fig. 1a) .
Histopathological analysis of Pbsn-cre4; Pten fl/fl mice at 1 and 2 months after castration identified the presence of a significantly greater amount of normal epithelium in castrated mice, indicative of a clear response to castration, compared to the non-castrated control mice (1 month: pathological index (PI) 0 = 25% versus 0 < 5% (P < 0.01); Supplementary Fig. 1a ; 2 months: PI 0 = 40% versus 0 < 5% (P < 0.01); Fig. 1b, left and Supplementary Fig. 1a ). Notably and in agreement with a previous report 14 , examination of dorsolateral prostate lobes from castrated mice with inactivation of Pten 3 months after castration showed a strong reduction in the amount of normal epithelium, indicating onset of acquired resistance to ADT (Fig. 1c, left and Supplementary Fig. 1a ). In sharp contrast to this finding, we did not observe any response in dorsolateral prostate lobes from either castrated mutant mice with combined inactivation of Pten and Zbtb7a (Fig. 1b,c, center and Supplementary Fig. 1a ) or mice with combined inactivation of Pten and Trp53 (Fig. 1b,c, right and Supplementary Fig. 1a) . These results indicate that loss of either Trp53 or Zbtb7a in a Pten-null genetic context confers de novo resistance to androgen deprivation in dorsolateral prostate tumors.
In line with reports in recent publications 15 , examination of the ventral prostate lobes of castrated mice with inactivation of Pten identified an intrinsic propensity of the tumors derived from this lobe to be resistant to ADT (PI 0 = 0%; Supplementary Fig. 1b) .
The anterior lobes of prostates from mice with inactivation of Pten alone and in combination with Zbtb7a or Trp53 were characterized by marked cystic dilation of prostate ducts 5 , a feature that prevents accurate pathological evaluation of the extent and severity of tumor lesions. Therefore, to assess ADT responses in this lobe, we quantified the tumor volume of anterior lobe lesions by MRI (Fig. 1d) . In line with the results described for the dorsolateral lobe, we observed that castration of mice with inactivation of Pten alone led to reduced tumor volumes ( Fig. 1d, top) , whereas no regression was observed in castrated mice that had concomitant inactivation of Zbtb7a (Fig. 1d, middle) or Trp53 (Fig. 1d, bottom) .
In accordance with the results obtained through physical castration, mice with inactivation of Pten alone showed sensitivity to chemical castration (using bicalutamide; as previously described 16 ), npg whereas those that also had inactivation of Zbtb7a or Trp53 showed resistance, thereby validating the notion that resistance to ADT is tumor intrinsic and not dependent on the specific treatment ( Supplementary Fig. 1c-f ).
Taken together, these data demonstrate that Pten-null prostate cancer is initially sensitive to androgen deprivation yet invariably acquires castration resistance. In contrast, our analysis clearly demonstrates that Pten and Zbtb7a double-null prostate cancers and Pten and Trp53 double-null cancers both have complete resistance to castration.
Genetic determinants of ADT response in human patients
We next determined whether the differential response to castration that we observed in the different mouse models would allow us to predict responses to ADT in human prostate cancer ( Fig. 2a) . To this end, we constructed a tissue microarray (TMA) designed to interrogate ADT response biomarkers by immunohistochemistry. The TMA included 84 biopsied specimens from prostatectomized human primary prostate cancer (of Gleason score 6 or 7) that had been treated with neoadjuvant ADT and showed variable response to the treatment, as measured by the ratio of circulating prostatespecific antigen (PSA) concentrations before and after ADT, the proliferation rate of prostate cells and the percentage of cells with nuclear androgen receptor (AR) localization ( Fig. 2b, Supplementary  Fig. 2a -c, Supplementary Table 2 and Supplementary Note). We performed an additional analysis to validate our stratification criteria. It has previously been reported that PSA concentrations of 10 ng/ml at diagnosis are frequently predictive of worse prognosis than levels below 10 ng/ml (reviewed in refs. 17, 18) . Thirty-one of the individuals with prostate cancer (out of 84 total) had a PSA concentration higher than 10 ng/ml before treatment with ADT in a neoadjuvant setting ( Supplementary Fig. 2c ). After 3 months of ADT, patients were classified as either good responders (16 patients) or poor responders (15 patients) on the basis of the ratio of PSA concentrations before and after treatment ( Supplementary Fig. 2c ). All patients that retained PSA concentrations of >10 ng/ml after ADT belonged to the category of poor responders (11 of 15), and none was found among the 16 good responders (P = 1.612 × 10 −5 ; Supplementary Fig. 2c ). Finally, we obtained and analyzed follow-up information for 36 of the 84 patients originally enrolled in this study. Notably, only 2 of 23 patients classified as good responders had developed resistance to ADT, whereas 6 of 13 were consistently classified as poor responders (P = 0.01; Supplementary Fig. 2d ). These data 
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A r t i c l e s further suggest the notion that the category of poor responders represents the group of patients most likely to develop tumor recurrence and castration-resistant distant metastases (reviewed in refs. 17, 18) . TP53 loss or mutation has been associated with tumor progression in a subset of human patients ( Supplementary Table 1 ) [6] [7] [8] [9] [10] [11] . Taking into account that p53 loss cannot be evaluated by immunohistochemistry, as protein levels are usually extremely low, we could only assess on our TMA mutational events that would result in p53 overexpression. Mutation in TP53 has been reported to correlate with progression to higher Gleason scores (4 + 3 or 4 + 4) and CRPC 6 , whereas the patients represented on our TMA had lower Gleason scores (mainly 3 + 3 and 3 + 4, as detailed in Supplementary Table 2 ). In agreement with these findings, in these earlier prostate cancer lesions from our cohort, we could not identify any sample with homogeneously elevated p53 immunohistochemical staining. We therefore interrogated a pre-existing array-based comparative genomic hybridization (aCGH) database consisting of 37 human prostate cancer metastases (28 of 37 were castration resistant) 11 . Of these castration-resistant metastatic samples, 43% (12 of 28) presented heterozygous loss of TP53, and 7% (2 of 28) presented homozygous loss, thereby confirming the relevance of loss of this tumor suppressor gene to CRPC.
We next focused our attention on PTEN and ZBTB7A and performed immunohistochemistry on our TMA samples with low Gleason scores ( Fig. 2c,d) . In this analysis, we observed no difference in mean PTEN loss in those patients who responded poorly or favorably to ADT (Fig. 2c) . In contrast, tumors harboring a significantly greater mean number of ZBTB7A-null cells stratified as poor responders to ADT (Fig. 2d) . Additionally, 15 samples of 84 showed both PTEN and ZBTB7A protein loss, including 4 from patients in the category of good responders (4/48 patients; 8.7%) and 11 in the category of poor responders (11/36 patients; 30.5%) (P = 0.0132; Fig. 2e ), suggesting that concomitant loss of PTEN and ZBTB7A stratifies with poor responsiveness to castration.
To mirror in humans the data obtained in genetic mouse models, we sought to assess in patients with prostate cancer whether concomitant genetic loss of ZBTB7A with PTEN might be a stronger indicator of CRPC development than loss of PTEN alone. To this end, we again interrogated the aCGH database of 37 human prostate cancer metastases (28 of 37 were castration resistant) 11 . We identified 336 genes undergoing genetic loss solely in castration-resistant specimens that were characterized by concomitant loss of PTEN in at least 80% of cases ( Supplementary Fig. 2e and Supplementary Table 3 ). Notably, 110 of these genes were located on the telomeric p arm of chromosome 19 (Supplementary Fig. 2e) , which includes the ZBTB7A gene ( Fig. 2f) . This observation suggests that, in humans, as predicted by our mouse study, there is a functional association between loss of PTEN and genetic deletion of ZBTB7A in CRPC development ( Fig. 2g and Supplementary Fig. 2f ).
The relevance of ZBTB7A loss in CRPC was further confirmed by the analysis of two other large pre-existing aCGH data sets of up to 58 and 50 human castration-resistant metastatic prostate cancer samples 19, 20 . ZBTB7A was found to be genetically lost in these two data sets in 26% of cases (15 of 58) and in 33% of cases (15 of 50) 19, 20 . In particular, 10 castration-resistant metastatic specimens out of 15 (67%) in the first data set 19 and 8 out of 15 (53%) in the second data set 20 showed specific deletion of the telomeric p arm of chromosome 19 that contains the ZBTB7A gene ( Fig. 2h and Supplementary  Fig. 2g ). Of note, in the data set recently published by Grasso and colleagues 20 , 2 of 3 described castration-resistant bone marrow metastases showed deletion of the telomeric p arm of chromosome 19 (WA48 and WA51), whereas the remaining metastasis (WA23) was characterized by a somatic missense alteration (p.Lys60Arg) in the BTB/POZ domain of ZBTB7A, a fundamental region for its transcriptional repressor activity 21 .
Finally, a similar result was also obtained by the analysis of the expression profile data set generated by Tomlins et al. 22 , where we observed a significant reduction in ZBTB7A expression in castrationresistant metastases (20) from several organs ( Fig. 2i) , thereby further corroborating a role for ZBTB7A loss in resistance to ADT.
Taken together, these data show that prostate cancers characterized by distinct genetic backgrounds differentially respond to ADT in mice as well as in humans and that ZBTB7A represents an unexpected player in the response of prostate cancer to androgen deprivation.
Biological responses to androgen deprivation
Castration typically results in a major decrease in prostatic mass, with the key molecular hallmarks including decreased proliferation and increased apoptosis 23 . Accordingly, we analyzed whether the absence of androgen differentially affected the proliferative index of these tumor types. To this end, we performed immunohistochemistry on the ventral, dorsolateral and anterior lobes of prostates from castrated mice using 
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A r t i c l e s the cellular proliferation marker Ki-67. In mice with inactivation of Pten, we observed at 1 month after castration a significant reduction in the overall proliferative index (Fig. 3a,b , left). In contrast, at 1 month after castration, we observed no difference in the proliferative index in any prostate lobe from mice with inactivation of both Pten and Zbtb7a (Fig. 3a,b , middle) or mice with inactivation of both Pten and Trp53 (Fig. 3a,b , right) compared to noncastrated controls. These findings suggest that Zbtb7a or Trp53 deletion in the Pten-null prostate epithelium confers the ability to proliferate in conditions of androgen depletion. Notably, no difference in Ki-67 staining was observed in the ventral lobes of prostates from the same mice (Supplementary Fig. 3a) .
We next measured the induction of apoptosis in the prostate epithelium of castrated mice with inactivation of Pten alone and in combination with Zbtb7a or Trp53. The induction of an early apoptotic response was observed in all lobes of the prostate and in all genotypes, as analyzed by measuring increased caspase-3 cleavage (Fig. 3c) . In contrast, Parp cleavage and pyknotic nuclei ( Supplementary Fig. 3b ), a feature of terminal apoptosis, were observed in all prostate lobes of castrated mice with inactivation of Pten (Fig. 3c ) but were completely absent in all lobes of castrated mice that also had inactivation of Zbtb7a or Trp53, indicating that there was apoptotic inhibition in these tumors.
We next investigated the effects of androgen withdrawal on AR localization in our different prostate cancer mouse genotypes. AR was predominantly translocated to the cytoplasm of prostate cells in all genotypes shortly after castration, as expected in the absence of androgen 24 (Fig. 3d, dorsolateral and anterior lobes and Supplementary Fig. 3c, ventral lobes) . However, quantitative immunohistochemistry analysis of prostates from castrated mice with concomitant inactivation of Pten and Zbtb7a or of Pten and Trp53 identified a modest but significant increase in the number of cells with nuclear AR compared to the prostates of castrated mice with inactivation of only Pten (Fig. 3e) , suggesting that cells switch to or harbor pre-existing alternative pathways of AR activation in Pten and Zbtb7a or Pten and Trp53 double-null CRPC.
In summary, these data suggest that Pten and Zbtb7a or Pten and Trp53 double-null prostate tumor cells, in contrast to cells only null for Pten, posses the ability to sustain androgen-independent proliferation while escaping the engagement of an apoptotic response.
XAF1 and SRD5A1 are key biomarkers for ADT response
Next, we sought to identify the molecular mechanisms underlying the differential sensitivity shown by prostate tumor cells from mice with inactivation of only Pten relative to those from mice with concomitant inactivation of Pten with Zbtb7a or Trp53 when challenged by androgen deprivation. For this purpose, we interrogated microarray gene expression profiles from mouse prostate specimens 4 . Notably, we observed significant downregulation (P = 1.07 × 10 −12 ) of Xaf1 (encoding X-linked inhibitor of apoptosis protein-associated factor-1; Fig. 4a ) in mice with 25 . A growing body of evidence has also demonstrated strong involvement of the XAF1-XIAP pathway in cell cycle regulation through yet unknown mechanisms [26] [27] [28] [29] [30] [31] [32] . The downregulation of Xaf1 was confirmed by quantitative RT-PCR (qRT-PCR), immunohistochemistry and protein blot analysis in specimens from mice with inactivation of both Pten and Zbtb7a (Fig. 4b-d) . Because XAF1 has recently been reported to be a p53-responsive gene 33 , we assessed Xaf1 levels in mice with inactivation of both Pten and Trp53. As expected, Xaf1 was significantly downregulated in prostates from these mice as measured by qRT-PCR, immunohistochemistry and protein blot analysis ( Fig. 4b-d) . Notably, immunohistochemistry for Xaf1 in dorsolateral prostate lobes from castrated mice with inactivation of Pten alone analyzed 3 months after castration showed reduced numbers of cells positive for staining compared to equivalent cells analyzed 1 month after castration, supporting the notion of Xaf1 as a good biomarker for castration resistance (Supplementary Fig. 4a ). Further interrogation of the expression profiles of prostates from mice with inactivation of both Pten and Zbtb7a identified significant upregulation of Srd5a1 (encoding 3-oxo-5-α-steroid 4-dehydrogenase 1) compared to prostates from mice with inactivation of only Pten (Fig. 4a) . The Srd5a1 and Srd5a2 enzymes catalyze the conversion of testosterone into dihydrotestosterone (DHT), a more potent and stable form of testosterone, and SRD5A1 is known to be frequently upregulated in human CRPC 34 . Production of DHT represents a key alternative mechanism that allows activation of AR in the context of the androgen levels present after castration 34 . qRT-PCR analysis of prostates from mice with concomitant inactivation of Pten with Zbtb7a or Trp53 confirmed Srd5a1 upregulation compared to prostates from mice with inactivation of Pten alone (Fig. 4e) , whereas no changes in the level of Srd5a2 transcript were observed (Supplementary Fig. 5a ). qRT-PCR analysis in dorsolateral prostate lobes from castration-resistant mice with inactivation of Pten analyzed 3 months after castration also showed higher levels of Srd5a1 compared to castration-sensitive prostates from mice of the same genotype analyzed 1 month after castration, whereas only a mild increase was observed in the levels of Srd5a2 (Supplementary Fig. 4b) .
Notably, whereas protein blot analysis of AR in dorsolateral lobes from castrated mice with inactivation of Pten analyzed 3 months after castration showed no difference in protein amounts compared to equivalent specimens analyzed 1 month after castration (Supplementary Fig. 4a) , immunohistochemistry analysis showed different localization of AR in the two contexts. In the castration-sensitive setting (1 month after castration), AR, as expected, was mainly localized in the cytoplasm. In contrast, AR was found to be nuclear 3 months after castration in large areas of the mutant Pten-null tumor, as is frequently observed in human prostate cancers that have acquired resistance to ADT 35 , and protein blot analysis showed higher levels of the AR transcriptional target Probasin (Supplementary Fig. 4a) .
To translate the relevance of biomarkers found in mice to the human context, we assessed the status of the XAF1 and SRD5A1 pathways in human prostate cancer. For this analysis, we performed immunohistochemistry with antibody to XAF1 on the custom TMA ( Fig. 4f) and quantified the number of cells that had downregulation of XAF1 (Fig 4f,  right) . In this analysis, we observed that there were lower amounts of XAF1 protein in human prostate cancer and that XAF1 staining was significantly lost in those patients that respond poorly to ADT (Fig. 4f) .
Furthermore, we analyzed the expression of XAF1, XIAP and SRD5A1 mRNA in several human prostate cancer expression arrays ( Fig. 4g-l) 11, [36] [37] [38] [39] . Notably, we observed that the expression levels of XAF1 were significantly decreased, in contrast to those of XIAP and SRD5A1, which were significantly increased, in the patients with the most aggressive prostate cancer, as characterized by high Gleason score, recurrence and metastasis ( Fig. 4g-l) . These data, combined with the results obtained in an androgen deprivation setting, suggest that downregulation of XAF1 and upregulation of SRD5A1 in prostate cancer with high Gleason score and metastasis might be predictive of poor sensitivity to ADT.
Embelin sensitizes castration-resistant prostate cancers to ADT
Our findings suggest a potential therapeutic modality based on the combination of ADT and an XIAP inhibitor for CRPC. Therefore, we treated the AR-mutant and DHT-sensitive LNCaP C4-2 cell line and the AR-null and DHT-insensitive DU145 and PC3 cell lines with the plantderived XIAP inhibitor embelin 32 and with ADT (charcoal/dextrantreated steroid-free medium (SFM)) as single agents and in combination (Supplementary Fig. 6a-d) . Whereas single treatment with SFM or embelin at concentrations of 5 µM for 4 d did not induce apoptosis, 
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A r t i c l e s the combination of embelin and SFM triggered a clear increase in the apoptotic response in LNCaP C4-2 cells, as measured by PARP cleavage (Supplementary Fig. 6a) . Notably, the combination of embelin and SFM along with MDV3100 (an experimental AR antagonist drug developed for the treatment of castration-resistant prostate cancer that is currently in Phase III clinical trial) markedly increased the apoptotic response in the LNCaP C4-2 castration-resistant cell line ( Supplementary  Fig. 6a) . Likewise, XIAP silencing, obtained through transient transfection with small interfering RNAs (siRNAs), induced apoptosis under SFM conditions (Supplementary Fig. 6b) , confirming the fundamental role of the XAF1-XIAP pathway in human CRPC. As expected, the ARnull DU145 and PC3 prostate cancer cell lines showed de novo resistance to the SFM and embelin combination treatment, as SFM (mimicking ADT) is unable to trigger any apoptotic response in these cell lines (Supplementary Fig. 6c,d) . Conversely, in these cells, ionizing radiation synergizes with embelin in triggering apoptosis 40 .
To corroborate our in vitro results in vivo, we next enrolled our castration-resistant mouse models with concomitant loss of Pten and Zbtb7a and of Pten and Trp53 in treatment programs with embelin and ADT. Specifically, we treated 4-month-old Pbsn-cre4; Pten fl/fl ; Zbtb7a fl/fl and 3-month-old Pbsn-cre4; Pten fl/fl ; Trp53 fl/fl mice with bicalutamide (Casodex) or embelin, alone and in combination. Although prostate cancers of both genotypes showed resistance to bicalutamide or embelin treatment as single agents ( Supplementary  Fig. 7a,b) , all prostate lobes showed marked tumor regression when treated with bicalutamide in combination with embelin ( Fig. 5a and Supplementary Fig. 7a,b) . Specifically, we found that treatment of prostate cancers of both genotypes with bicalutamide and embelin was characterized by a profound reduction in the proliferation rate ( Fig. 5b-e) , which, in the case of prostate cancers with inactivation of Pten and Zbtb7a, was also accompanied by rescue of the apoptotic response (Fig. 5f,g and Supplementary Fig. 7c,d) .
These findings clearly demonstrate that castration-resistant prostate tumors characterized by the impairment of the XAF1-XIAP pathway become sensitive to ADT when treated with the XIAP inhibitor embelin.
ADT, embelin and dutasteride for the treatment of CRPC
We hypothesized that management of CRPC could further benefit from the addition of an SRD5A1 inhibitor to the combination therapy with embelin and ADT. Notably, the SRD5A1 inhibitor dutasteride is currently used in clinical trials in combination with ADT for the treatment of advanced prostate cancer (see URLs) [41] [42] [43] .
At first, therefore, we treated the VCaP, LNCaP and 22RV1 human prostate cell lines with embelin, dutasteride and ADT as single agents and in triple combination. The combination of embelin, dutasteride and SFM induced an even more potent apoptotic response compared to each combination of pairs of these agents-embelin plus SFM and dutasteride plus SFM (Fig. 6a-d and Supplementary Fig. 6e,f) .
We next treated castration-resistant 4-month-old Pbsn-cre4; Pten fl/fl ; Zbtb7a fl/fl and 3-month-old Pbsn-cre4; Pten fl/fl ; Trp53 fl/fl mice with ADT in combination with embelin and dutasteride. Both Pten and Zbtb7a as well as Pten and Trp53 double-null prostate tumors showed a further significant decrease in tumor burden after treatment with bicalutamide, embelin and dutasteride in combination compared to treatment with bicalutamide and embelin together (Fig. 6e) .
These findings clearly demonstrate that castration-resistant prostate tumors characterized by the impairment of the XAF1-XIAP and SRD5A1 pathways are sensitized to ADT when treated with embelin and dutasteride, thereby rendering this triple combination an effective new therapeutic approach to the treatment of patients with CRPC genetically stratified by XAF1, XIAP and SRD5A1.
DISCUSSION
Our data support the hypothesis that the response to ADT is dictated by the genetic make-up of prostate cancer. Our findings argue that genetic mouse models can be extremely valuable in tailoring the administration of standard-of-care treatments on the basis of genetic and molecular stratification.
We find that Pten loss-driven prostate cancer exhibits an overall reduction in tumor volume in response to castration, indicating that this genetic mouse model is initially sensitive to androgen deprivation. Nevertheless, the mice show a rapid recurrence of prostate cancer at 3 months after castration. CRPC development in Pten-null prostate cancer seems to be accompanied by concomitant downregulation of Xaf1, upregulation of Srd5a1 and relocalization of AR to the nucleus (Supplementary Fig. 4a) .
This model of acquired resistance is consistent with the initial response patterns and invariable latent resistance observed in human subjects with prostate cancer. Notably, we have now shown that concomitant Zbtb7a or Trp53 deletion abrogate the response of Pten-null tumors to ADT.
Castration-resistant prostate cancers associated with loss of Zbtb7a and Trp53 show low levels of Xaf1, a phenomenon that potentially explains the lack of both apoptosis induction and proliferation arrest.
The key role of the Xaf1 pathway is further highlighted by the observation that XIAP is highly upregulated during prostate cancer progression and CRPC, both in humans 44 and in mice (Supplementary Fig. 5b) . Accordingly, we have shown that the XIAP inhibitor embelin, when combined with ADT, potently suppresses tumor growth in vitro, confirming what was previously reported 45 , and in vivo in our castrationresistant genetic mouse models.
We also found that CRPCs in mice double null for Pten and Zbtb7a and for Pten and Trp53, as well as Pten-null CRPCs, are characterized by the upregulation of Srd5a1 (ref. 35 ) and, notably, that dutasteride (SRD5A1 inhibitor) further increases the prostate tumor response to embelin and ADT.
We think our integrated mouse and human analysis has identified potential new therapeutic strategies. Patients with prostate cancer characterized by XAF1-XIAP and SRD5A1 deregulation are likely to quickly develop CRPC; thus, ADT in such patients should be combined with embelin and dutasteride (Supplementary Fig. 7e) .
In sum, our study demonstrates the validity of a cross-species integrated genetic approach for the evaluation of prostate cancer therapies. A particularly powerful aspect of the approach is the combined access it affords to data regarding genetic and molecular differences between tumors, whether in human patients or mouse models. Notably, this study has led to the identification of key pathways and genetic alterations dictating responses to standard-of-care therapeutic modalities, as well as new druggable biomarkers, for overcoming resistance to such treatments. This approach can be customized for any tumor type when appropriate genetic mouse models are available and for testing of experimental targeted therapies 1, 46 . The applications of an integrated approach to the field of human cancer therapy are significant and potentially transformative.
were enabled, and the area was set to 0.15. For percentage analyses, a nuclear threshold for each biomarker was set as follows: PTEN, 0.288; ZBTB7A, 0.08. For cytoplasmic staining, the following parameters were set: the inner distance to nuclei was 0, the outer distance to nuclei was 7, the minimum size (pixel) was 1, and the threshold was 0.56. For percentage analyses, a cytoplasmic threshold for each biomarker was set as follows: PTEN, 0.066; ZBTB7A, 0.056. For each core, the DAB intensity of each biomarker for each cell was determined by InForm. With a threshold applied, InForm calculated the percentage of cells that were positive for each biomarker in the nucleus, in the cytoplasm and in both compartments. TMA cores that were difficult to classify owing to technical limitations (complications with tissue presentation or core loss) were removed from all analyses. For the current analysis, of the 87 cases represented on the 2 TMAs, 3 were removed because of insufficient representation on the TMA (core loss). For all data metrics obtained, tissue samples were reviewed by a trained pathologist to ensure appropriate assignment of scores.
In vitro treatments. VCaP, LNCaP, LNCaP C4-2, 22Rv1, PC3 and DU145 human prostate cancer cells were purchased from the American Type Culture Collection (ATCC), cultured in DMEM or RPMI (as indicated by the ATCC) supplemented with 10% FBS and tested for mycoplasma contamination every month. For androgen deprivation and drug treatments, regular medium supplemented with 10% FBS was replaced with regular medium supplemented with 10% charcoal/dextran-treated FBS (HyClone) (SFM) and 10 µM dutasteride and/or 10 µM MDV3100 and/or 5 µM embelin for 2 or 4 d. For siRNA experiments, cells were transfected with siRNA to XIAP (obtained from Dharmacon), and, 72 h after transfection, regular medium supplemented with 10% FBS was replaced with regular medium supplemented with 10% SFM. For protein blotting, cells were lysed in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid and 0.1% SDS) supplemented with protease inhibitors (Complete, Roche), briefly sonicated and resolved by SDS-PAGE. Proteins were transferred to nitrocellulose membranes and detected by chemiluminescence after incubation with antibodies against PARP (9554, Cell Signaling Technology; 1:1,000 dilution), XIAP (2042, Cell Signaling Technology; 1:1,000 dilution), AR (PG21, Millipore; 1: 3,000 dilution), β-actin (A5316, Sigma-Aldrich; 1:5,000 dilution), GAPDH (14C10, Cell Signaling Technology; 1:6,000 dilution) and ZBTB7A (clone 13E9, hamster hybrodoma supernatant; 1:1,000 dilution).
In vivo treatments. Chemical castration studies in mice were conducted with bicalutamide (Casodex) at a dose of 10 mg/kg by oral gavage, daily for 5 d a week for 4 weeks. Tumor-bearing mice were treated with a combination of bicalutamide (10 mg/kg) and the XIAP inhibitor embelin (60 mg/kg) in 0.1% carboxymethyl cellulose (CMC; as vehicle) by oral gavage, daily for 5 d a week for 4 weeks. Triple-treatment experiments were conducted with bicalutamide (10 mg/kg), the XIAP inhibitor embelin (60 mg/kg) in 0.1% CMC, administered by oral gavage, 3 d a week, bicalutamide (10 mg/kg) and the Srd5a1 inhibitor dutasteride (2 mg/kg) in 0.1% CMC, administered by oral gavage, 2 d a week for 4 weeks. Mice were euthanized, and tumors were dissected, weighed and processed for histopathology and molecular analyses at the conclusion of these studies.
Statistical analysis.
Results are expressed as mean ± s.d. Comparisons between groups were assessed using Student's t-test analysis. P ≤ 0.05 was considered significant. 
